OmniAb

Drug discovery specialists at Ligand take their antibody biz public via SPAC, aiming to build $850M company
Endpoints
Thu, 03/24/22 - 10:51 am
Ligand Pharmaceuticals
drug discovery
OmniAb
SPACs
Ligand to split in half, spinning OmniAb platform into its own company
Endpoints
Wed, 11/10/21 - 10:26 am
Ligand Pharmaceuticals
OmniAb
antibody discovery
drug discovery
spinoffs